New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:08 EDTARWRArrowHead Research publishes results regarding company's Dynamic Polyconjugate
Arrowhead Research announced the publication of data demonstrating that high level target gene knockdown with low doses of cholesterol-siRNA is possible in non-human primates using the company's Dynamic Polyconjugate delivery system and a novel co-injection strategy. This new delivery approach dramatically increases the efficacy of cholesterol-siRNA and, together with the co-injection strategy, simplifies the manufacturing process to enable a commercially scalable delivery vehicle for RNAi therapeutics. The company is using this strategy and a next generation DPC polymer in ARC-520, its hepatitis B clinical candidate. The paper titled, "Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated siRNAs in vivo," was published online ahead of print in the journal Nucleic Acid Therapeutics to be featured in the December issue
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
10:06 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD GME YOKU SPLS DKS WUBA ARWR ACHN
August 20, 2014
11:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 19, 2014
10:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 18, 2014
10:57 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 15, 2014
10:41 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT UVXY MNKD KING VIX SVXY VXX RAX OPK
August 14, 2014
11:46 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
10:20 EDTARWRHigh option volume stocks
Subscribe for More Information
09:15 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:56 EDTARWRArrowhead should trade up on Hep B data, says RBC Capital
RBC Capital said Arrowhead's initial top-line Phase IIa data showed good knockdown of s-antigen, durability, and safety. The firm expects shares to trade up on the news and notes doctors say increased doses and time could lead to higher cures of Hep B. Shares are Outperform rated.
07:36 EDTARWRArrowhead shares recommended after ARC-520 data at Deutsche Bank
Subscribe for More Information
06:35 EDTARWRArrowhead shares likely weak on lack of data, says Piper Jaffray
Piper Jaffray expects shares of Arrowhead to be under pressure following the company's Q3 results given the lack of data for ARC-520 for the treatment of hepatitis-B virus infection. Piper keeps an Overweight rating on the stock with a $24 price target.
August 12, 2014
19:02 EDTARWROn The Fly: After Hours Movers
Subscribe for More Information
16:16 EDTARWRArrowhead Research provides update on phase 2a study of ARC-520
Arrowhead Research completed its dosing of 1mg/kg and 2mg/kg dose cohorts. The company's initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previously. ARC-520 continues to be well tolerated, with no dropouts or serious adverse events reported. The overall rate of AEs has been lower in the phase 2a than in the phase 1 normal volunteer study and safety labs continue to show no indication of end organ toxicity. The company received IRB and DSMB approvals to proceed and began enrolling an additional dose cohort at 3 mg/kg in the Phase 2a patient study.
16:13 EDTARWRArrowhead Research reports Q3 EPS (22c), consensus (22c)
Total operating expenses for the quarter were $12.7M, compared to $6.4M for the quarter ended June 30, 2013. The company’s cash and investments of cash were $188.5M at June 30.
August 8, 2014
06:28 EDTARWRArrowhead Research volatility elevated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use